Skip to content

Assessment of Risk in Chronic Airways Disease Evaluation

Assessment of Risk in Chronic Airways Disease Evaluation (ARCADE)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01656421
Acronym
ARCADE
Enrollment
767
Registered
2012-08-03
Start date
2011-05-31
Completion date
2019-04-30
Last updated
2019-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Brief summary

Patients with chronic obstructive pulmonary disease (COPD) have an increased risk of cardiovascular disease,osteoporosis, muscle wasting and diabetes mellitus. Cardiovascular disease is a major cause of death in such patients and it may be related to excess stiffening of the walls of major arteries, such as the aorta, and it has been suggested to represent premature aging. However, there is little known of the development of these problems, which were previously considered to be due to smoking and which is now known not to be the only factor. The investigators will study a large group of patients with mild to very severe airflow obstruction based on the NICE 2010 classification of severity and a matched comparator group free of COPD. This study involves three assessments of the development of the complications of COPD over a five year period. The key measure will be the rate of change in the aortic wall stiffness, an accepted indicator of the risk of heart disease. Changes in wall stiffness will be related to the severity of lung disease; other known cardiovascular risk factors, such as high blood pressure, increased blood cholesterol and to cardiovascular events including heart attacks and death; and to the presence of other complications, such as osteoporosis, muscle wasting and diabetes mellitus. These measures will be analysed in the context of changes in bodywide inflammation and metabolic function and the changes in the rate of ageing. This increased knowledge of interacting factors in the complications of COPD is likely to lead to studies of treatments to avoid their development.

Interventions

None listed

Sponsors

GlaxoSmithKline
CollaboratorINDUSTRY
Cardiff Metropolitan University
CollaboratorOTHER
Cardiff University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Previously Proven COPD or at risk of developing COPD

Exclusion criteria

* Pregnancy * A history of malignancy in the last 5 years * Unable to give informed consent or diagnosed dementia * Renal or hepatic failure * Active endocrine disorder eg., Addison's disease, hypothyroidism * Any other disease identified as having an inflammatory or metabolic component, eg. rheumatoid disease * Disorders affecting mobility, eg. Parkinson's disease, cerebrovascular accident.

Design outcomes

Primary

MeasureTime frameDescription
Aortic Pulse Wave Velocity (arterial stiffness)Baseline, 2 and 5 yrsRate of change in aortic pulse wave velocity in patients with COPD over a period of 5 years and its relationship to cardiovascular morbidity and mortality.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026